Nuvilex Contracts With Clinical Network Services Pty Ltd for Late-Phase Clinical Trials in Pancreatic Cancer

SILVER SPRING, Md., April 15, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has contracted Clinical Network Services Pty Ltd (CNS), a fully integrated drug development company based in Australia, New Zealand and the United Kingdom, to handle every aspect of Nuvilex's late-phase clinical trials in pancreatic cancer as Nuvilex's Contract Research Organization (CRO). The trials, which will focus on treatment for advanced stage pancreatic cancer, will involve Nuvilex's pancreatic cancer treatment (a combination of the proprietary "Cell in-a-Box(R)" live-cell encapsulation technology and the cancer drug ifosfamide) which has already proved effective in early stage trials.

Nuvilex Engages ViruSure to Establish Cell Banks for Phase 2b Clinical Trials in Pancreatic Cancer

SILVER SPRING, Md., April 10, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that it has signed a Master Services Agreement with ViruSure GmbH, located in Vienna, Austria, to develop and maintain Master, Working and End of Production Cell Banks. These cell banks are necessary steps in the production of the cells to be encapsulated using the Cell-in-a-Box(R) technology for Nuvilex's Phase 2b clinical trials in advanced, inoperable pancreatic cancer to be conducted in Australia.

Medical Marijuana Sciences' Dr. Mark L. Rabe Speaks at ASA Medical Cannabis Unity Conference in Washington DC

Cell-in-a-Box(R) Live-Cell Encapsulation and Anti-Cancer Properties of Cannabinoids Emphasized

SILVER SPRING, Md., April 8, 2014 (GLOBE NEWSWIRE) -- Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that Dr. Mark L. Rabe's presentation at the National Medical Cannabis Unity Conference, held this past weekend in Washington DC, prompted numerous questions and a lively discussion on Nuvilex's proprietary Cell-in-a-Box(R) platform and how Medical Marijuana Sciences is working to combine it with the cancer-fighting properties of cannabinoids.

Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic Cancer

Nuvilex Retains TD2 to Conduct Preclinical and Clinical Studies

SILVER SPRING, Md., April 1, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Master Services Agreement with Translational Drug Development (TD2) pursuant to which TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex's pancreatic cancer and other treatments utilizing Cell-in-a-Box(R) technology.

Nuvilex to Present at National Medical Cannabis Unity Conference in Washington DC

Dr. Mark L. Rabe to Speak on "Unique Applications for Cannabinoid Chemotherapy Therapy"

SILVER SPRING, Md., March 25, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that holistic and medical marijuana expert Dr. Mark L. Rabe, Chairman of the Scientific Advisory Board of Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., will deliver a significant presentation at the 2nd Annual National Medical Cannabis Unity Conference "Navigating Medical Cannabis in the Mainstream" that will be held in Washington, DC April 5-7, 2014. Dr. Rabe's presentation will take place at the Mayflower Hotel on April 6.

Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory Board

Dr. Brian Salmons Indispensable for Development of Cannabis-based Cancer Treatments

SILVER SPRING, MD, March 11, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Brian Salmons, Ph.D., CEO and President of Nuvilex’s partner Austrianova, to its Scientific Advisory Board. 

Nuvilex Appoints Dr. Garret L. Yount to Its Subsidiary's Scientific Advisory Board

Dr. Yount's Expertise in Preclinical Use of Cannabinoids Against Cancer Cells Invaluable for Developing Cannabinoid-Based Cancer Treatments

SILVER SPRING, Md., March 7, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Garret L. Yount, Ph.D. to its Scientific Advisory Board.